• Proceedings of the KSAR Conference
• /
• 2001.03a
• /
• pp.50-50
• /
• 2001

혈액형을 지배하는 유전자는 진화에 대하여 중립적인 작용을 하고 있어서 집단의 유전적 구조의 특성 파악, 계통분류학 등에 많이 응용되고 있다. 본 연구는 칡소에 대한 유전학적 특성을 구명하고자 혈액형 분석기술을 응용하여 실시하였다. 공시동물은 (주)한경게놈텍 목장에서 사육중인 외모적으로 칡소의 특징을 보이는 25두를 이용하였다. 혈액은 경정맥에서 헤파린 처리된 진공 채혈관에 무균적으로 채취하여 혈장, 백혈구 및 적혈구로 원심분리한 후 냉동 혹은 냉장 보관하여 각 실험에 이용하였다. 적혈구 항원형의 검출은 2% 적혈구 부유액과 축산기술연구소에서 생산된 항혈청 11종을 이용하여 용혈반응으로 실시하였고, 혈액단백·효소를 지배하고 있는 6개의 유전자 좌위에 대하여 전분 혹은 포리아크릴 아미드겔 전기영동으로 다형 검출을 실시하였다. 용혈반응으로 검출한 적혈구 항원형의 반응양상은 검사한 11종의 항체에 대하여 6종은 50%이상의 개체에서 양성반응을 보였다. 이와 같은 결과는 일반 한우에서 보이는 양성반응율보다는 높은 것으로 판단되어진다. 전기영동법으로 분석한 6개의 혈액단백·효소 지배 유전자 좌위 중 ALB좌위을 제외한 5개 유전자 좌위에서 다형이 관찰되었다. HB, AMY-1, GC 및 PTF-2 유전자 좌위는 2개의 대립유전자가 관찰되었고, TF 유전자 좌위는 4개의 대립유전자가 관찰되었다. 표 1에서 같이 칡소에서 관찰된 각 유전자 좌위의 대립유전자 빈도의 구성은 일반적인 한우와는 상이한 결과를 보였으나 평균 이형접합도는 칡소가 0.438, 일반한우가 0.442로 계산되어 유전적 변이성은 유사한 것으로 추정되었다. 이상의 결과로 본 연구에서 분석한 칡소는 다른 한우집단과는 상이한 유전적 구조를 가지고 있으나, 유전적 다형성은 비교적 높은 것으로 시사되었다. 보다 정확하고 많은 량의 유전정보 수집을 위하여 Microsatellite DNA 및 모색 관련 유전자를 분석할 필요성이 있을 것으로 사료된다.(Table Omitted)

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1994.04a
• /
• pp.320-320
• /
• 1994

Carboxyethylgermanium sesquioxide(Ge-132)를 투여용량(300,600, 900mg/kg)과 투여일을 변화시켜 정상마우스와 cyclophosphamide(CY)로 처리한 마우스에 경구투여한 후, Ge-132가 CY 에 의해 변화된 마우스의 면역기능에 미치는 효과를 실험하였다. SRBC 항원 주사전, 동시 또는 후에 Ge-132를 투여시 SRBC에 대한 적혈구 응집소가와 비장세포의 용혈반 형성세포(PFC)수가 항원 주사일과 관계없이 용량의존적으로 증가되어 체액성 면역반응을 강화시켰으며, 마크로파지의 탐식능도 항진시켰다. 그러나 DNFB에 대한 접촉성 지연형 과민반응은 DNFB 감작일과 투여용량에 관계없이 Ge-132투여로 억제되었다. CY를 투여한 마우스에 Ge-132를 병용 투여한 군이 CY 단독 투여군에 비하여 적혈구 응집소가와 PFC수 및 혈중 탄소입자의 제거율이 현저하게 증가되어, CY로 억제된 체액성 면역반응과 마크로파지의 탐식능이 항진된 것으로 나타났다. DNFB 감작 전 CY 투여로 증폭된 접촉성 지연형 과민반응이 Ge-132 병용투여로 감소되어 CY로 유도된 면역독성 반응에 대한 Ge-132의 저지효과를 시사해 주었다.

• Tuberculosis and Respiratory Diseases
• /
• v.48 no.3
• /
• pp.339-346
• /
• 2000

Background : The moot important prognostic factor in non-small cell lung cancer is the TNM stage. Even after complete resection in early non-small cell lung cancer, the five-year survival rate is still low. However, new prognostic factors, including molecular biologic factors, have recently been found to guide the treatment of patients with non-small cell lung cancer. We evaluated the prognostic value of the loss of blood-group antigen A in tumor tissue, which has been implicated as an important prognostic factor for overall survival and the timing of the disease progression. Methods : The loss of blood-group antigen A was assessed immunohistochemically in paraffin-embedded tumor samples from 26 patients with blood types A or AB, who had undergone curative surgery. Monoclonal antibody was used to detect the blood group antigen A expression. Results : Fifteen patients (58%) expressed antigen A in their tumor tissue, whereas 11 patients (42%) did not show antigen A. The median survival time of the blood A antigen positive group was 11 months, while the median survival time of the blood A antigen negative group was 18 months. The difference in survival between the two groups was not statistically significant. Conclusion : The loss of blood-group antigen A in tumor tissue was not found to be a significant prognostic factor in patients with non-small cell lung cancer. This study needs to be extended for further evaluation.

• Korean Journal of Clinical Laboratory Science
• /
• v.48 no.1
• /
• pp.36-40
• /
• 2016

Red blood cell (RBC) alloimmunization results from genetic disparity of RBC antigens between donor and recipients. The discrepancy of RBC antibody screening test occurs when the results of red cell tests do not agree with those of the serum test. In order to select the proper blood units for transfusion, clarification of the cause of discrepancies is essential. The RBC antibody screening test is an easy, quick, and reliable method for detection of clinically significant antibodies. Antibody screening and identification is recommended prior to transfusion to determine whether there is blood group incompatibility. We reported that phenotyping for E, D, M, E+c, and C+e antibody screening test should be extended. Therefore, these results indicate that anti-D and anti-E alloantibodies were major risk factors for haemolytic disease of the newborn or delayed haemolytic transfusion reactions in this study population. We suggested that its antibody screening be adapted to blood safety interventions. Targeted screening of selected recipients at risk offers less value than universal antibody screening, and more research is needed to determine the real incidence of this national condition.

• Journal of Life Science
• /
• v.16 no.7 s.80
• /
• pp.1109-1111
• /
• 2006

The present study was carried out to investigate the blood markers of the Korean native horse. A total number of 158 horses were tested using microhaemagglutination with 11D system reagents (Da, Db, Dc, Dd, De, Df, Dg, Dh, Dk, Dm and Dn). Of the 158 horses, 3 horses showed an unusual D system phenogroups; these phenogroups may be silent (null) alleles, De or Dk and Dc, respectively. Dacdfgm, Dacdfgmn, and Ddegmn phenogroups were recognized. These results present basic information for detecting the genetic markers among the Korean native and alien horses.

• Korean Journal of Veterinary Research
• /
• v.39 no.6
• /
• pp.1066-1072
• /
• 1999

The present study was carried out to investigate the blood markers of Cheju horses. The red cell types (blood groups) were tested from 73 Cheju native horses and 118 Cheju racehorses by serological procedures with 23 reagents. The blood group phenotypes observed with high frequency were Pb(34.3%), Qc(56.2%), Qb(15.1%) and genotypes Dbcm/dghm(12.3%), Dde/dghm(9.6%), Dad/bcm(6.8%), Dcgm/de(6.8%) in Cheju native horses, while Aa(63.6%), Pa(44.9%), P-(28.8%), Qabc(36.4%), Dbcm/cgm(14.4%), Dbcm/bcm(10.2%), Dbcm/de(7.6%), Dbcm/dghm(5.1%), Dde/dk(5.1%) in Cheju racehorses. Alleles observed with high frequency were Ab(0.128), Ac(0.169), Dad(0.103), Dadn(0.075), Ddghm(0.226), Pb(0.316), Qc(0.494) in Cheju native horses and Aa(0.529), Dbcm(0.306), P-(0.531), Qabc(0.197), Q-(0.504) in Cheju racehorses. No specific variation of blood groups and allele frequencies of C,K,U system were observed in Cheju native horses and Cheju racehorses. The mean heterozygosity in Cheju native horses and Cheju racehorses was observed 0.5344 and 0.5102, respectively.

• The Korean Journal of Blood Transfusion
• /
• v.29 no.3
• /
• pp.282-290
• /
• 2018

Background: Anti-E or paired anti-E/-c antibodies can develop in patients with the Rh CDe phenotype. This study examined the differences in transfusion in patients with the CDe phenotype according to formation of anti-E or anti-E/-c antibodies. Methods: Retrospective reviews were carried out on the results of antibody identification tests performed in 2014. The Rh phenotype and antibody specificity were investigated. The transfusion and medical records of patients with the CDe phenotype were examined. Results: In total, 76 patients were included in the review. Of these 76 patients, 38 (50.0%) were of the CDe phenotype. Anti-E antibodies were the most frequent (60.5%), followed by anti-E/-c antibodies (23.7%). The total transfusion units and platelet transfusion units were significantly higher in patients with anti-E/-c antibodies (P=0.028 and P=0.01, respectively). The distribution of categorized diseases was similar in the patients with the anti-E and anti-E/-c antibodies. A frequency of transfusion episodes greater than or equal to four was higher in patients with hepatobiliary diseases (85.7%). Conclusion: In CDe phenotype patients, platelet transfusion was significantly higher in the anti-E/-c positive group than the anti-E positive group, indicating that platelets play a role in red blood cell alloimmunization. Because E is the most immunogenic antigen in Korea, it is important to define the disease group, in which patients with CDe phenotype require a transfusion of E and c-negative blood.

• The Korean Journal of Blood Transfusion
• /
• v.23 no.2
• /
• pp.173-179
• /
• 2012

We report on two cases of anti-$Jk^a$, whose reactivity disappeared on an antibody identification test using enzyme-treated red cells. One of two patients was a 72-year-old female with cirrhosis of the liver and colon cancer, and the other was a 55-year-old female with known MDS and incomplete Behcet's disease. Results of an antibody identification test using a LISS/Coombs gel card (DiaMed AG) showed negative to one positive with red cells having the $Jk^a$ antigen; however, all reactions using the enzyme-treated cells showed negative results, which was unexpected. The patients' RBC phenotype was Jk(a-b+). We obtained positive results in reactions of enzyme-treated $Jk^a+$ cells and EDTA using a patient's serum and proved that the cause of the negative reaction might be complement-related.

• Biomolecules & Therapeutics
• /
• v.6 no.1
• /
• pp.50-55
• /
• 1998

Antigenic potential of a recombinant human erythropoietin (rhEPO) produced by Dong-A charm. Co. Ltd. was examined by active systemic anaphylaxis (ASA) test in guinea pigs, mouse-rat passive cutaneous anaphylaxis (PCA) reaction and passive hemagglutination (PHA) test. In ASA test, rhEPO induced the signs of restlessness, rubbing or licking nose, sneezing and coughing in the animals immunized with rhEPO 1000 lU/kg alone or rhEPO 1000 lU/kg incorporated into Freund\\\\`s complete adjuvant. In the mouse-rat PCA test, only one of six sera from the animals immunized with rhEPO 1000 lUng incorporated into Alum showed positive result. In the PHA test, rhEPO revealed negative results in all of the rhEPO-immunized groups. From these results, rhEPO was considered to produce IgE in guinea pigs and mice, but not IgG and/or IsM in mice. The results of this study were similar to those of the other recombinant human erythropoietin and these positive results were thought to be caused due to the fact that rhEPO were heterogeneous proteins to guinea pigs and mice. Considering the fact that rhErO has an identical structure with indigenous human erythropoietin, rhEPO is not thought to cause immunological problems in clinical use.

• The Korean Journal of Blood Transfusion
• /
• v.23 no.2
• /
• pp.169-172
• /
• 2012

Lutheran a antigen ($Lu^a$) is detected in 6 to 8% of Caucasians and Africans. In Korean and other Asian populations, it is very rare or nearly absent. Therefore, although $Lu^a$ has a considerable immunizing capacity, sensitization to $Lu^a$ is a rare event. Here we report on a rare case of anti-$Lu^a$ in a 70 year-old female patient with Lu (a-/b+) phenotype and review the relevant literature. Due to the paucity of $Lu^a$ positive panel cells in antibody screening and identification tests, detection of this rare antibody to $Lu^a$ antigen is not feasible. Therefore, we should keep in mind the possibility of the misleading false negative result in detection of antibody to this low incidence antigen.